Search results: Found 4

Listing 1 - 4 of 4
Sort by
An Updated View on an Emerging Target: Selected Papers from the 8th International Conference on Protein Kinase CK2

Authors: --- --- ---
ISBN: 9783038424130 9783038424123 Year: Pages: 320 DOI: 10.3390/books978-3-03842-413-0 Language: English
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Medicine (General)
Added to DOAB on : 2017-07-12 07:57:21
License:

Loading...
Export citation

Choose an application

Abstract

The 8th International Conference on Protein Kinase CK2 (www.uks.eu/ck2), organized by Matthias Montenarh and Claudia Götz, will be held at the Faculty of Medicine of Saarland University, in Homburg, Germany, from 6–9 September, 2016.Protein kinase CK2 is a serine/threonine kinase, which is highly conserved in evolution. Knock-out experiments have shown that this enzyme is absolutely necessary for cell viability. The enzyme is highly expressed in rapidly proliferating cells, which goes along with an elevated enzyme activity. Protein kinase CK2 is involved in a broad range of signaling pathways, regulating proliferation, differentiation, apoptosis, or senescence. Recent advances towards the characterization of the three-dimensional structure of protein kinase CK2 and its subunits will undoubtedly yield important new insights into its regulation, and the functions of CK2. Moreover, with two inhibitors of the enzyme presently in clinical phase II trials, human protein kinase CK2 has appeared as an emerging target for cancer diseases.

Mitogen Activated Protein Kinases

Authors: --- ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889453399 Year: Pages: 163 DOI: 10.3389/978-2-88945-339-9 Language: English
Publisher: Frontiers Media SA
Subject: Science (General) --- Biology
Added to DOAB on : 2018-02-27 16:16:45
License:

Loading...
Export citation

Choose an application

Abstract

Mitogen-activated protein kinase (MAPK) pathways are evolutionarily conserved in all eukaryotes and allow cells to respond to changes in the physical and chemical properties of the environment and to produce an appropriate response by altering many cellular functions. MAPKs are among the most intensively studied signal transduction systems. MAPK research is a very dynamic field in which new perspectives are continuously opening to the scientific community. Importantly, many MAPK inhibitors have been developed during the last years and are currently being tested in preclinical and clinical assays for inflammatory diseases and cancer treatment. In this research topic, we have gathered 14 papers covering recent advances in different aspects of the MAPK research area that have provided valuable insight into the spatiotemporal dynamics, the regulation and functions of MAPK pathways, as well as their therapeutic potential. We hope that this Research Topic helps readers to have a better understanding of the progresses that have been made recently in the field of MAPK signalling. A deeper understanding of the these pathways will facilitate the development of innovative therapeutic approaches.

Keywords

MAPK --- p38 --- ERK --- JNK --- MSK --- kinase --- scaffold --- cancer --- inflammation --- cell differentiation

Current Knowledge in Thyroid Cancer — From Bench to Bedside

Author:
ISBN: 9783038424765 9783038424772 Year: Pages: VIII, 212 DOI: 10.3390/books978-3-03842-477-2 Language: English
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Biology
Added to DOAB on : 2017-08-11 11:32:17
License:

Loading...
Export citation

Choose an application

Abstract

In recent years, studies in the field of thyroid cancer have been performed in order to identify and verify thyroid specific biomarkers, as well as cancer-specific changes in gene expression patterns and alterations of the protein content. Furthermore, new drugs, small molecules and antibodies were developed and tested in vitro and in vivo. Trials investigated the ratio between therapeutic and adverse effects. Tyrosine kinase inhibitors (TKI) have become a new therapeutic option of both differentiated thyroid cancer and medullary thyroid cancer. In the last few years, new substances for targeted systemic therapy have been approved after their efficacy was demonstrated in Phase III trials. Most of them show a moderate response. However, adverse effects are common. TKI are used in patients with advanced metastatic thyroid cancer that is radioiodine (RAI)-refractory.In this Special Issue, original studies on the pathophysiology, diagnosis, and therapy of thyroid cancer, including genetics, proteomics, metabolomics, molecular and cell biology, will be published. It will also cover reports on patients, providing novel mechanistic insights into the underlying pathogenesis or new aspects that may impact clinical therapy, and recent study results in order to review the current status of new therapy options in thyroid cancer.

Second Line Treatment of Non-Small Cell Lung Cancer: Clinical; Pathological and Molecular Aspects of Novel Promising Drugs

Authors: ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889452637 Year: Pages: 84 DOI: 10.3389/978-2-88945-263-7 Language: English
Publisher: Frontiers Media SA
Subject: Medicine (General)
Added to DOAB on : 2018-02-27 16:16:44
License:

Loading...
Export citation

Choose an application

Abstract

Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therapeutic options are reserved to a minor part of lung cancer patients harbouring specific mutations. In the so called wild type population, the first line options bring the median overall survival to go beyond 1 year, and in the population receiving the maintenance therapy over 16 months. Given these results, more than 60% of patients may receive a second line therapy with further opportunities to improve the length and quality of life. For patients not harbouring targetable DNA mutations newer options will be available for second line therapeutic schemes and two major assets seem to be promising: immune modulation and anti-angiogenetic agents. In particular, anti PD1/PDL1 antibodies, VEGFR antibodies and TKIs, these latter combined with standard chemotherapy docetaxel advance the median overall survival of 12 months. These drugs have a different mechanism of action, various adverse events and their activity is different depending on the types of population. However, the biomarkers’ activity and efficacy prediction are not fully or totally understood. In addition, also for patients with DNA targetable mutations new drugs seems to be promising for the use in the second line therapeutic protocols. In particular, drugs selectively directed against ALK translocation and mutational events and EGFR T790M secondary mutations seems to be very promising. In this Research Topic we critically discuss the older therapies and the historical development of second line, putting in to perspective the new agents available in clinical practice. We discuss their importance from a clinical point of view, but also consider and exploit the complex molecular mechanisms responsible of their efficacy or of the subsequently observed resistance phenomena. In this perspective, the undercovering and characterization of novel predictive biomarkers by NGS technology, the characterization of novel actors in the signal transduction pathway modulating the response of the cells, the optimization of new diagnostic tool as the evaluation of liquid biopsy and the implementation of more suitable pre-clinical models are crucial aspects dissected too. Nivolumab, nintedanib and ramucirumab probably will give the opportunity to improve the efficacy outcomes for the treatment of wild type tumours in second line therapeutic schemes, but many aspects should be debated in order that these agents are made available to patients, planning ahead a therapeutic strategy, beginning from the first line therapy, to the subsequent ones in a logical and affordable manner. As well, for treatment of mutated tumours, mutated EGFR irreversible inhibitors such as rociletinib and AZD9291, and ALK targeting drugs ceritinib and alectinib will also play an important role in the immediate future. Probably the right way is to give all the available opportunities to patients, but challenges and pitfalls should be carefully debated, and by launching this Research Topic we tried to give some practical insights in this changing landscape.

Listing 1 - 4 of 4
Sort by
Narrow your search

Publisher

Frontiers Media SA (2)

MDPI - Multidisciplinary Digital Publishing Institute (2)


License

CC by (2)

CC by-nc-nd (2)


Language

english (4)


Year
From To Submit

2017 (4)